Olodanrigan

Cat. No.:	HY-13106
CAS No.:	1316755-16-4
Molecular Formula:	$C_{32}H_{29}NO_5$
Molecular Weight:	507.58
Target:	Angiotensin Receptor
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 34 mg/mL (66.98 mM)

H_2O : 0.1 mg/mL (0.20 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Mass / Solvent / Concentration	1 mg	5 mg	10 mg
1 mM	1.9701 mL	9.8507 mL	19.7013 mL
5 mM	0.3940 mL	1.9701 mL	3.9403 mL
10 mM	0.1970 mL	0.9851 mL	1.9701 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].

In Vivo

EMA401 (10 mg/kg; p.o.) results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI)[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Pharmacol Sci. 146 (2021) 121-124.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.Lancet. 2014 May 10;383(9929):1637-47.

[2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.

[3]. Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA